SCHEMBL5363452

SCHEMBL5363452

CCOC(=O)c1cc2cc(F)cc(Br)c2n1C(C)CNC(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 6/20 0.36
SYK P43405 1/20 0.35
SERPINE1 P05121 1/20 0.35
ABCB1 P08183 1/20 0.33
TSHR P16473 2/20 0.33
ALDH1A1 P00352 3/20 0.32
PCSK9 Q8NBP7 1/20 0.32
MAPT P10636 1/20 0.32
NOD2 Q9HC29 1/20 0.32
NOD1 Q9Y239 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
EPAS1 Q99814 1/20 0.31
GPR119 Q8TDV5 1/20 0.31
KDM4E B2RXH2 1/20 0.31
POLB P06746 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2A P29274 1/20 0.31
KCNQ4 P56696 2/20 0.31
KCNQ5 Q9NR82 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5363447 1.00 AAK1 (0.36) AAK1SYKSERPINE1ABCB1TSHR
SCHEMBL15563422 0.91 AAK1 (0.33) AAK1ABCB1TSHRALDH1A1MAPT
SCHEMBL4044928 0.86 SYK (0.39) AAK1SYKSERPINE1ABCB1TSHR
SCHEMBL4038865 0.86 SYK (0.39) AAK1SYKSERPINE1ABCB1TSHR
SCHEMBL4042108 0.85 AAK1 (0.39) AAK1SYKSERPINE1ABCB1TSHR
SCHEMBL4042104 0.85 AAK1 (0.39) AAK1SYKSERPINE1ABCB1TSHR
SCHEMBL5357070 0.83 NOD2 (0.38) SYKSERPINE1ABCB1TSHRALDH1A1
SCHEMBL4044170 0.83 AAK1 (0.38) AAK1SYKSERPINE1ABCB1TSHR
SCHEMBL5357064 0.83 NOD2 (0.38) SYKSERPINE1ABCB1TSHRALDH1A1
SCHEMBL5359194 0.83 AAK1 (0.38) AAK1SYKSERPINE1ABCB1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253281-B2 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
US-20070106076-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles BENTLEY JONATHAN M 2007-05-10 US disclosed
US-20050239789-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles BENTLEY JONATHAN M 2005-10-27 US disclosed
EP-1325008-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-10-05 EP disclosed
US-6933387-B2 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles HOFFMANN-LA ROCHE INC. (US) 2005-08-23 US disclosed
US-20030216401-A1 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles F. HOFFMANN-LA ROCHE AG (CH) 2003-11-20 US disclosed
US-20020035110-A1 Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) 2002-03-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239789-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles GPR119, INSR, GIPR AAK1 1113/4885SYK 3413/4885SERPINE1 3768/4885
US-20030216401-A1 Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles GPR119, INSR, IRS1 AAK1 319/4885SYK 4160/4885SERPINE1 2358/4885
US-20070106076-A1 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles GPR119, INSR, GIPR AAK1 1113/4885SYK 3413/4885SERPINE1 3768/4885
US-20020035110-A1 Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles GPR119, HTR1D, HTR1A AAK1 686/4885SYK 3324/4885SERPINE1 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.